Fagoterapia LAB (FL) is the pioneering biotech company in Italy with a mission to save patients' lives from infections caused by lethal antibiotic-resistant bacteria through the use of bacteriophages. To achieve this breakthrough, FL has developed a platform approach centered around two key proprietary assets:

1. A comprehensive collection (biobank) of natural, well-characterized phages capable of eradicating infection-causing bacteria.

2. A cutting-edge AI algorithm trained on genomic data from bacteria and viruses, enabling it to rapidly identify the most effective phage mix against a specific pathogenic bacterium within minutes.Starting with the genome analysis of the bacterium causing the resistant infection in a patient, FL has implemented an integrated end-to-end process to produce a customized antibacterial drug in just 7-10 days (a substantial improvement compared to the 6-8 week timeline of global competitors). This drug is composed of the most potent phages selected from their collection based on the algorithm's recommendations.

FL's platform approach enables the treatment of any type of bacterial infection.To validate their phage-based therapeutics, FL will initiate scientific trials, initially focusing on two types of infections and two target pathogens prioritized by the WHO due to their low number of new cases per year, making them eligible for Orphan Drug designation:

1. Nosocomial genito-urinary infections acquired by Klebsiella pneumoniae (Italy's focus: 6,000 new cases/year; up to 3 hospital admissions/year; risk of sepsis; mortality rate up to 40%).

2. Prosthetic joint infections caused by Pseudomonas aeruginosa (Italy's focus: 1,000 new cases/year; up to 2 hospitalizations/year; expected at least 15 years of chronic disease; high morbidity, e.g., amputation).Notably, Fagoterapia LAB currently stands as the sole active player in Italy dedicated to the development of phage-based medicines.